KMT2A and acute lymphoblastic leukemia: Similar to ALL models, AML PDX models have been used to study targeted therapies, including FLT3 inhibitors in FLT3/ITD AML PDX models and menin inhibitors in KMT2A-rearrangement (KMT2A-r) AML51,56,57.